Lv1
30 积分 2024-06-23 加入
A prospective phase 2 study of combination epigenetic therapy against relapsed/refractory peripheral T cell lymphoma
12小时前
待确认
Safety and activity of CTX130, a CD70-targeted allogeneic CRISPR-Cas9-engineered CAR T-cell therapy, in patients with relapsed or refractory T-cell malignancies (COBALT-LYM): a single-arm, open-label, phase 1, dose-escalation study
16小时前
已完结
Long-Term Follow-Up of the Prospective Randomized AATT Study (Autologous or Allogeneic Transplantation in Patients With Peripheral T-Cell Lymphoma)
16小时前
已完结
Prognosis and risk stratification of peripheral T-cell lymphomas
16小时前
已完结
Inebilizumab for Treatment of IgG4-Related Disease
8天前
已完结
Brentuximab vedotin plus cyclophosphamide, doxorubicin, etoposide, and prednisone followed by brentuximab vedotin consolidation in CD30-positive peripheral T-cell lymphomas: a multicentre, single-arm, phase 2 study
12天前
已完结
JSH practical guidelines for hematological malignancies, 2023: II. Lymphoma-1. Follicular lymphoma (FL)
13天前
已完结
JSH practical guidelines for hematological malignancies, 2023: II. lymphoma—overview
13天前
已完结
Decoding RAS mutations in thyroid cancer: A meta-analysis unveils specific links to distant metastasis and increased mortality
16天前
已完结
Clinicopathological significance of major fusion oncogenes in papillary thyroid carcinoma: An individual patient data meta-analysis
16天前
已完结
皖公网安备34019202002308
